Education
About Us
Working with TipRanks
Follow Us
Autolus Therapeutics Plc (AUTL)
NASDAQ:AUTL
AUTL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.11 - $5.00
Previous CloseN/A
Volume359.61K
Average Volume (3M)1.61M
Market Cap
$383.21M
Enterprise Value$608.52M
Total Cash (Recent Filing)$120.67M
Total Debt (Recent Filing)$258.00K
Price to Earnings (P/E)―
Beta2.18
Next Earnings
May 01, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding266,128,900
10 Day Avg. Volume2,208,332
30 Day Avg. Volume1,605,929
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)44.29
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-480.29
Enterprise Value/Ebitda-3.01
Forecast
1Y Price Target
$8.67Price Target Upside502.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Autolus Therapeutics News
PremiumCompany Announcements
Autolus Therapeutics Announces Leadership Transition in Finance
PremiumCompany Announcements
Autolus Therapeutics: Positive Momentum Amid Financial Challenges
PremiumCompany Announcements
Autolus Therapeutics Reports Strong 2024 Results
---
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressMAA review is ongoing in the EU and U.K. with potential approvals expected.
Safety And Business CaseAUTL noted Aucatzyl's better safety and a better business case, allowing centers to treat more patients and hence greater profit.
Treatment Centers Expansion33 US treatment centers now authorized for Aucatzyl, potentially able to reach ~60% of US patients.
Bears Say
BNTX Option Not ExercisedBNTX did not exercise its option for AUTO1/22 in pediatric B-ALL.
Lack Of Financial GuidanceManagement did not provide guidance on sales or patient numbers due to difficulties in projecting these figures.
---
Ownership Overview
― Insiders
13.34% Mutual Funds
0.18% Other Institutional Investors
85.59% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AUTL FAQ
What was Autolus Therapeutics Plc’s price range in the past 12 months?
Autolus Therapeutics Plc lowest stock price was $1.10 and its highest was $5.00 in the past 12 months.
What is Autolus Therapeutics Plc’s market cap?
Autolus Therapeutics Plc’s market cap is $383.21M.
When is Autolus Therapeutics Plc’s upcoming earnings report date?
Autolus Therapeutics Plc’s upcoming earnings report date is May 01, 2025 which is in 9 days.
How were Autolus Therapeutics Plc’s earnings last quarter?
Autolus Therapeutics Plc released its earnings results on Mar 20, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.206 by $0.116.
Is Autolus Therapeutics Plc overvalued?
According to Wall Street analysts Autolus Therapeutics Plc’s price is currently Undervalued.
Does Autolus Therapeutics Plc pay dividends?
Autolus Therapeutics Plc does not currently pay dividends.
What is Autolus Therapeutics Plc’s EPS estimate?
Autolus Therapeutics Plc’s EPS estimate is -0.25.
How many shares outstanding does Autolus Therapeutics Plc have?
Autolus Therapeutics Plc has 266,128,900 shares outstanding.
What happened to Autolus Therapeutics Plc’s price movement after its last earnings report?
Autolus Therapeutics Plc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.206. Following the earnings report the stock price went down -13.402%.
Which hedge fund is a major shareholder of Autolus Therapeutics Plc?
Currently, no hedge funds are holding shares in AUTL
---
Autolus Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.67 (502.08% Upside)
$8.67 (502.08% Upside)
Blogger Sentiment
Bullish
AUTL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.14%
12-Months-Change
Fundamentals
Return on Equity
-81.91%
Trailing 12-Months
Asset Growth
108.51%
Trailing 12-Months
Company Description
Autolus Therapeutics Plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
---
AUTL Company Deck
---
AUTL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment, highlighting the successful U.S. launch of AUCATZYL, strong financial backing, and promising clinical data. However, financial challenges remain with increased operating and net losses, as well as high R&D expenditures.Read More>---
AUTL Stock 12 Month Forecast
Average Price Target
$8.67
▲(502.08% Upside)
Technical Analysis
Best Analysts Covering AUTL
1 Year
---